A Study of SHR-1501 Alone or in Combination With BCG or SHR-1316 in Subjects With NMIBC

Clinical trial NCT05410730 · RECRUITING

Trial details

NCT number: NCT05410730
Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

High-risk NMIBC

Start date: 2022-11-23
Primary completion: 2025-05-01
Enrollment: 150

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.